STAT NewsOriginal article
STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized
RegulatoryPositive
AI Analysis
Summary
The FDA's TEMPO pilot program has accepted four generative AI medical devices, including products from Cadence and Limbic, allowing digital health companies to release products without prior marketing authorization.
Outcome Details
Four AI devices accepted into FDA's TEMPO pilot program allowing release without marketing authorization
Importance:6/10
Sentiment:
0.60
FDAgenerative AImedical devicesdigital healthregulatory pathwayTEMPO pilot
Read the original article
Published by STAT News on September 3, 2026 8:30 AM